Welcome to our dedicated page for Esperion Therape news (Ticker: ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therape stock.
Esperion Therapeutics develops and commercializes therapies for cardiometabolic and rare/orphan diseases, with a commercial focus on oral, once-daily, non-statin LDL-C treatments for patients at risk for cardiovascular disease. Company news commonly covers NEXLETOL bempedoic acid data, CLEAR Outcomes analyses, dyslipidemia guideline developments, financial results, business updates, and material agreements.
Esperion's news also reflects portfolio expansion through its completed acquisition of Corstasis Therapeutics and Enbumyst bumetanide nasal spray, an FDA-approved loop diuretic for edema associated with congestive heart failure and hepatic or renal disease in adults. Additional recurring topics include ACLY biology, product commercialization, pipeline work in Primary Sclerosing Cholangitis and renal diseases, and governance or capital-structure matters.
Esperion (NASDAQ: ESPR) has scheduled its second quarter 2025 financial results announcement for August 5, 2025, before market open. The company will host a webcast at 8:00 a.m. ET to discuss the results and provide business updates.
Esperion is a commercial-stage biopharmaceutical company developing FDA-approved oral, once-daily, non-statin medicines for cardiovascular disease patients with elevated LDL-C. Their medications are supported by the 14,000-patient CLEAR Cardiovascular Outcomes Trial. The company is also advancing its next-generation program focusing on ATP citrate lyase inhibitors (ACLYi) development.
Esperion (NASDAQ: ESPR) has reached a settlement agreement with Accord Healthcare Inc. regarding patent litigation over NEXLETOL, a bempedoic acid medication. Under the agreement, Accord Healthcare has committed not to market a generic version of NEXLETOL in the United States before April 19, 2040, except under specific limited circumstances.
The company continues to pursue patent litigation against several other defendants, including Alkem Laboratories, Aurobindo Pharma, Dr. Reddy's Laboratories, MSN Pharmaceuticals, Renata Limited, and Sandoz. The outcome of these ongoing patent disputes remains uncertain regarding potential generic versions of NEXLETOL and NEXLIZET entering the U.S. market before 2040.
Esperion (NASDAQ: ESPR) has appointed Craig Thompson, current CEO of Cerevance, to its Board of Directors as an independent director, expanding the board to eight members. Thompson brings over 20 years of biopharmaceutical industry leadership experience and currently serves as CEO of Cerevance, a clinical-stage biotechnology company.
Thompson's extensive experience includes leadership roles at several pharmaceutical companies, notably serving as President & CEO of Neurana Pharmaceuticals, COO at Tetraphase Pharmaceuticals, and Chief Commercial Officer at Trius Therapeutics, where he was involved in its $700+ million acquisition by Cubist Pharmaceuticals. His background also includes senior positions at Pfizer and Merck & Co., where he led significant cardiovascular product initiatives.
Esperion (NASDAQ: ESPR) has announced its participation in two major investor conferences in June 2025: the Jefferies Global Healthcare Conference in New York on June 4 at 1:25 p.m. ET, and the Goldman Sachs Global Healthcare Conference in Miami on June 9 at 10:40 a.m. ET.
The company, a commercial stage biopharmaceutical firm, specializes in FDA-approved oral, once-daily, non-statin medicines for patients with cardiovascular disease and elevated LDL-C. Their medications are supported by the CLEAR Cardiovascular Outcomes Trial involving nearly 14,000 patients. Esperion is also developing next-generation ATP citrate lyase inhibitors (ACLYi) and expanding globally through commercial execution and international partnerships.
Esperion (NASDAQ: ESPR) has reached a settlement agreement with Micro Labs USA, Inc. and its affiliate regarding patent litigation over NEXLETOL. The settlement prevents Micro Labs from marketing a generic version of NEXLETOL in the United States before April 19, 2040, except under specific limited circumstances. The agreement resolves the litigation initiated by Esperion in response to Micro Labs' Abbreviated New Drug Application (ANDA). However, patent litigation continues with eight other defendants, including Accord Healthcare, Alkem Laboratories, Aurobindo Pharma, Dr. Reddy's Laboratories, Hetero USA, MSN Pharmaceuticals, Renata Limited, and Sandoz Inc., with no guarantee of preventing generic versions before 2040.
Esperion (NASDAQ: ESPR) has announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference scheduled for May 20, 2025, at 10 a.m. ET. The event will be webcasted and accessible through Esperion's website, with replay available for approximately 90 days after the presentation.
Esperion is a commercial-stage biopharmaceutical company that develops FDA-approved oral, once-daily, non-statin medicines for patients with cardiovascular disease and elevated LDL-C. Their medications are supported by the CLEAR Cardiovascular Outcomes Trial involving nearly 14,000 patients. The company is also advancing its next-generation program focusing on ATP citrate lyase inhibitors (ACLYi) development.
Esperion (NASDAQ: ESPR) has granted 49,300 restricted stock units (RSUs) to 15 new employees under its 2017 Inducement Equity Incentive Plan. The RSUs will vest 25% on the one-year anniversary of the recipient's vesting commencement date, with the remaining 75% vesting in twelve equal quarterly installments thereafter, subject to continued employment. The grants were made as employment inducements under NASDAQ Rule 5635(c)(4).
Esperion is a commercial-stage biopharmaceutical company developing FDA-approved oral, once-daily, non-statin medicines for cardiovascular disease patients with elevated LDL-C. Their medications are supported by the CLEAR Cardiovascular Outcomes Trial involving nearly 14,000 patients. The company is also advancing its next-generation program focusing on ATP citrate lyase inhibitors (ACLYi).
Esperion Therapeutics (NASDAQ: ESPR) has entered into a license and distribution agreement with HLS Therapeutics for exclusive commercialization rights of NEXLETOL and NEXLIZET in Canada. The agreement includes an upfront payment, milestone payments up to $5 million, and tiered royalties on product sales. Esperion will supply the finished product at a profitable transfer price.
The partnership aims to address a significant market, as approximately 2.6 million Canadian adults live with diagnosed heart disease, which is the second leading cause of death in Canada. HLS will handle commercialization, reimbursement, and marketing responsibilities in Canada, while Esperion maintains product supply duties.